Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.
Also called NCT01667614
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 136 participants
- Registry
-
NCT01667614
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Iran
- Registry status
- Completed
Technical summary
Registry record NCT01667614. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Diabetic Nephropathy
- Condition
- Essential Hypertension
- Intervention (Drug)
- spironolacone 25 mg tablets added to losartan
- Lead sponsor
- Tehran University of Medical Sciences
Record details
- Record id
cardio:ct-nct01667614- Content hash
451055bcd831737052c04e7f16663cd3900e3fa07da3485efd4cceb150126fac